160 results about "Ganglion" patented technology

Disclosed herein are methods for treating impairment of a limb in a subject. Particular methods comprise applying a therapeutically effective amount of an electrical stimulus to dorsal roots, dorsal rootlets, or dorsal root ganglia, of sensory neurons innervating the limb of the subject, wherein the impairment is a motor impairment and / or a proprioception impairment due to neurological disorder or injury, the electrical stimulus is applied with one or more electrodes controlled by a neurostimulator, and the one or more electrodes are implanted in the epidural space at the dorsolateral aspect of the spinal cord and proximate to the dorsal roots or dorsal rootlets of the sensory neurons innervating the limb of the subject, or the one or more electrodes are implanted proximate to dorsal root ganglia of sensory neurons innervating the limb of the subject.

The invention relates to the technical field of phototherapy, in particular to a wearable light blood sugar reducing device and system and an eyeshade. The wearable light hypoglycemic device comprises a wearing unit for a user to wear; the lighting unit is used for projecting red light to human eyes; the driving unit is used for supplying power to the lighting unit; and the control unit is used for adjusting the light-emitting mode of the lighting unit according to a preset regulation and control scheme. According to the preset regulation and control scheme, multiple times of illumination are carried out within preset time, and the interval between every two adjacent times of illumination is preset duration. Red light waves of a specific wave band can be emitted to human eyes according to a preset regulation and control scheme, photosensitive retinal ganglion cells (ipRGCs) can be directly activated, signals are transmitted from optic nerves to series nerve nuclei of hypothalamus and medulla oblongata, finally, the signals act on peripheral brown adipose tissue BAT through sympathetic nerves, the metabolic capacity of blood sugar is affected, and the blood sugar metabolism is improved. And when the embodiment is used for reducing blood sugar, the user only needs to wear the equipment, so that the method is easy to implement.

The invention discloses a retina bionics-driven super-resolution reconstruction model and an implementation method thereof. The reconstruction model is composed of a shallow extraction and lateral suppression module (LIM) and a deep feature extraction and reconstruction module (RM). The shallow layer extraction simulates the processing process of photoreceptor cells in a biological vision system on optical signals, and low-level feature information is extracted from a low-resolution image so as to realize primary processing of image signals; the side inhibition module LIM simulates a horizontal cell side inhibition mechanism to capture signals, and performs different intensity inhibition on features; the deep feature extraction adopts multi-layer feature fusion and a layered structure, imitates multiple functions of bipolar cells, gradually extracts and fuses feature information of different layers, and improves the naturalness of the whole image; the reconstruction module RM is composed of an up-sampling block and a convolution, simulates ganglion cells, and is responsible for generating a final high-resolution reconstruction image. According to the method, a satisfactory reconstruction result is obtained for an image in a complex scene, and meanwhile it is proved that a retina biological system is feasible to be migrated to an image super-resolution reconstruction technology.

The present invention relates to a nucleic acid sequence derived from a regulatory region of a human Lgr5 gene and having promoter activity in retina non-long-process cells. The invention also relates to an expression cassette or vector comprising the promoter, a viral particle or cell comprising the expression cassette or vector, and a pharmaceutical composition comprising the expression cassette or vector and the viral particle or cell. The invention also relates to the use of the expression cassette, vector, viral particle, cell or pharmaceutical composition in the treatment of eye diseases, especially diseases associated with retinal ganglion cell degeneration.

A nervous system emulator engine includes working computational models of the vertebrate nervous system to generate lifelike animal behavior in a robot. These models include functions representing several anatomical features of the vertebrate nervous system, such as spinal cord, brainstem, basal ganglia, thalamus, and cortex. The emulator engine includes a hierarchy of controllers in which controllers at higher levels accomplish goals by continuously specifying desired goals for lower-level controllers. The lowest levels of the hierarchy reflect spinal cord circuits that control muscle tension and length. Moving up the hierarchy into the brainstem and midbrain / cortex, progressively more abstract perceptual variables are controlled. The nervous system emulator engine may be used to build a robot that generates the majority of animal behavior, including human behavior. The nervous system emulator engine may also be used to build working models of nervous system functions for clinical experimentation.

The invention discloses a two-dimensional organic / inorganic heterojunction photoelectric nerve component and a preparation method thereof, and belongs to the technical field of photoelectric devices. According to the invention, a TMDC material MoS2 is transferred to a substrate through a mechanical stripping method, then a film electrode is plated on a MoS2 layer through an electron beam lithography method, and finally a single-layer Me-PTCDI crystal is epitaxially grown on the MoS2 layer through a back-off method to form the heterojunction. Due to the formation of the MoS2 / Me-PTCDI heterojunction, the photoelectric nerve device has excellent photosensitivity and light adaptability, and can simulate reactions of retinal essential photosensitive ganglion cells under different illumination; the device can make current change under the stimulation of light pulses so as to simulate the generation and action of human melatonin, and can realize visual adaptation in bright and dark environments under the regulation and control of grid voltage, and the device has a wide application prospect in the field of automatic driving due to the corresponding characteristics.

A sphenopalatine ganglion (SPG) stimulating device for stimulating an SPG of a patient is provided. The SPG stimulating device includes a sheath having a proximal end portion and a distal end portion, the distal end portion shaped to define at least one electrode opening. A nasal stabilizer is disposed around the sheath and configured to stabilize the sheath with respect to a nostril of a nose of the patient when the sheath is disposed within the nose. An electrode mount is slidably disposed within the sheath, and at least one electrode is coupled to the electrode mount and deployable out of the sheath through the at least one electrode opening to position the at least one electrode to stimulate the SPG. Other applications are also described.

The invention discloses a near-infrared light controllable irradiator for astroganglion stimulation, which comprises a physiological signal acquisition module used for acquiring a near-infrared light sensing signal of a carotid artery area in real time; the signal processing module is used for performing variational mode decomposition on the near-infrared sensing signal and extracting a heart rate component; the autonomic nerve analysis module is used for receiving the heart rate component and calculating the excitement ratio of sympathetic nerves to parasympathetic nerves; a deep learning model is arranged in the control signal generation module, and an optical parameter control signal is generated according to the heart rate cycle characteristics and the excitement ratio; and the light adjusting module is used for receiving the light parameter control signal so as to control the emission of near-infrared light. According to the invention, the output of the infrared light can be adjusted according to the physiological signal of the human body, intelligent adjustment is realized, the near-infrared light stimulation better fits the individual condition, and the pertinence and effectiveness of the stimulation are effectively improved.

In certain embodiments a light therapy system (e.g., phototherapy device), such as for treatment of Alzheimer's disease, depression, dementia, short-term memory, or for improved learning, improved athletic performance or improved cognitive performance, is provided where the light system comprises a blue light source that operates at a frequency in the range from 20 to 50 Hz (preferably around 40 Hz), whereby the system enables retinal ganglion cells of a human to be exposed in order to stimulate brain waves (gamma oscillations in the human's brain).

An ultrasound-nuclear magnetism / CT registration method for dorsal root ganglion positioning is characterized in that a rib is used as an auxiliary mark of an auxiliary positioning image section, and accurate registration and image fusion of an ultrasound image and a nuclear magnetism / CT image are completed through the characteristic that the relative distance between a transverse process and the rib is fixed. And finally, the purpose of accurately positioning the dorsal root ganglion is achieved. The method is simple and easy to implement, high in accuracy and capable of effectively solving the problem that the dorsal root ganglion cannot be accurately positioned on the ultrasonic image, and the puncture treatment effect of the dorsal root ganglion is improved.

The invention relates to a navigation positioning system for sphenoid palate ganglions. The system comprises a data processing modeling module which is used for acquiring a preoperative multi-modal image data set, extracting sphenoid palate ganglion features of an image, and generating an individualized anatomical model reflecting individual anatomical differences; the path planning module extracts boundary features of a key structure based on an individual anatomical model, generates an acupuncture path set and a candidate path set by adopting a path planning algorithm, and determines optimal acupuncture approach parameters. And the guide track generation module calculates the spatial attitude of the instrument by using a quaternion transformation algorithm according to the optimal acupuncture approach parameters, and generates a dynamic guide track. And the deviation correction updating module predicts a motion track through a Kalman filtering algorithm, calculates a real-time path deviation value, updates output parameters of a navigation system according to the deviation value, and finally generates an acupuncture guide path. By adopting the system, the position difference of the sphenoid palate ganglion and the adjacent tissues thereof can be effectively captured, and a whole-process accurate navigation support is provided for sphenoid palate ganglion acupuncture stimulation.

There is provided a transvenous cryoneurolysis system and method for accessing and targeting neural treatment sites to relieve a variety of clinical indications, including peripheral neuropathy. A neurosome approach is described that includes one or more target nerves to receive selective cryoneurolysis via a target vein. The system performs a variety of freeze-thaw cycles via the target vein to induce a desired axial cryolesion along a target nerve. The target nerves and veins are selected to combine the treatment of the identified neurosome for pain relief in addition to the regenerative properties of cryoneurolysis.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for relieving side effects of oxaliplatin chemotherapy. The traditional Chinese medicine composition composed of radix paeoniae alba and liquorice is used for relieving various side reactions caused by oxaliplatin, wherein the side reactions comprise peripheral neurotoxicity, hematological toxicity and systemic reaction. The traditional Chinese medicine composition plays a role in relieving peripheral neurotoxicity caused by oxaliplatin through multiple ways, on one hand, neuroinflammatory response in dorsal root ganglions is inhibited, the dorsal root ganglions are responsible for receiving and conducting sensory nerve impulse, the injury is mainly represented as sensory disorders such as numbness of hands and feet, stabbing pain and delayed feeling, and on the other hand, the neuroinflammatory response in the dorsal root ganglions is inhibited; therefore, OIPN can be relieved by inhibiting the inflammatory reaction; on the other hand, the blood flow of microvessels is promoted, and the circulation disorder of the microvessels at the tail ends of the limbs is improved to relieve OIPN. Moreover, the traditional Chinese medicine composition does not influence the anti-tumor effect of oxaliplatin, is good in safety, and does not damage important organs such as heart, liver, spleen, lung and kidney.

The invention relates to a control method of optical acupuncture, which comprises the following steps: a control system continuously applies a plurality of optical stimulation pulses lower than a nerve excitation threshold value, and target acupuncture point nerves enter a subcritical energy storage state through membrane potential superposition after synapse; laser output intensity is increased, and a directional threshold crossing pulse is emitted to trigger nerve discharge; judging the principal axis direction of local tissue fibers, and adjusting the laser incident angle, so that a light beam penetrates along the principal axis direction to trigger compliant tissue resonance; two beams of frequency differential laser are used for cross irradiation in a non-treatment acupoint area needing suppression to form fixed interference fringes, and a minimum power drop point is calculated to cover and suppress a target acupoint, so that the acupoint is always in an interference offset zone in the treatment process to form a selective function suppression window; a control system synchronously collects heart rate and respiration signals of a user, extracts respective periods to calculate a minimum common rhythm, sets a subsequent light stimulation rhythm as a physiological rhythm differential resynchronization frequency, and enables alternating resonance activation of different neural rhythms through phase staggering.

The present invention discloses a method for reprogramming fibroblasts into autonomic ganglion organoids. The method uses a TetO-controlled lentiviral system to establish a method for reprogramming mouse somatic cells into autonomic ganglion organoids (induced autonomic ganglion, iAG) using a combination of transcription factors; the experimental results show that the combination of three transcription factors, Ascl1, Phox2a / 2b and Hand2, can induce mouse embryonic fibroblasts to generate self-organized, network-connected neural clusters. The method shows that the three factors Ascl1, Phox2a / 2b and Hand2 are effective means for reprogramming mouse fibroblasts into iAG organoids, and the induced iAG organoids may be used as a model to decipher the pathogenesis of autonomic neurological diseases and screen effective sources of drugs and cell replacement therapy.

The invention belongs to the field of medicinal chemistry, and particularly relates to application of specific spiro chalcone compounds in preparation of neuroprotective drugs and drugs for treating nerve injury related diseases, and the spiro chalcone compounds can antagonize cell excitatory injury and cell apoptosis caused by amino acid. In a middle cerebral artery occlusion (MCAO) mouse model, E38 can reduce cerebral infarction area, improve neurological score and alleviate retinal ganglion cell (RGC) injury. In an optic nerve pinch injury model, the X38 can effectively improve retinal thinning and optic nerve electrophysiological function loss caused by optic nerve injury.

The invention relates to a system for activating nerve cells in the human eye and brain for enhancing the residual vision in existing visual-field defects, for reducing or correcting other visual disturbances or cognitive deficits by means of neurostimulation, in particular non-invasive application of microcurrent to the head, more particularly non-invasive transcranial alternating current stimulation (tACS), the system consisting of: a non-invasive applicator for guiding a flow of energy to the eye and brain and for stimulating the blood flow and activation of nerve cells, in particular retinal ganglion cells and brain cells; an impulse generator for generating electrical or magnetic stimulation signals; and a data-processing and control unit for providing patient-specific stimulation signal sequences; wherein the applicator comprises for example at least two electrodes, which can be brought into contact with the head of the test subject and in this respect stimulation electrodes, in particular replaceable stimulation electrodes, are fixed on the applicator such that they rest or make contact on the right and left of the eye in the region of the temple of the patient's head; wherein the stimulation signal sequences are provided repeatedly for application until a demonstrable reduction in an existing vascular dysregulation in the eyes and in the brain is determined.

The invention provides an optic nerve regulation and control system based on an ultrasonic technology, a first ultrasonic module is deployed on the outer side of a target human eyelid and is provided with an Archimedes spiral type first ultrasonic array facing the human eye, and the first ultrasonic array is configured to generate a gathered ultrasonic beam which acts on a human eye retina ganglion cell area in a targeted manner; the positioning module is deployed on the outer side of a target human eyelid and is configured to measure three-dimensional geometric data when a human eyeball horizontally faces the front and measure the depth distance of a human eye retina ganglion cell area in the human eye; the optic nerve response prediction module is pre-trained with an optic nerve response prediction model facing a target human body, and the optic nerve response prediction model is configured to adjust sound intensity output of the first ultrasonic array based on stimulation feedback prediction of human eye retina ganglion cells. According to the invention, the optic nerve regulation and control system satisfies non-intrusive, high-precision and self-adaptive requirements, and has optic nerve regulation and control and repair functions.

The present invention discloses a percutaneous puncture balloon device for compressing both the semilunar ganglion and the third ramus of the trigeminal nerve. The device comprises a catheter, wherein an inner balloon is provided on the outer wall of the catheter near the operating end, and an outer balloon is provided over the inner balloon. The catheter comprises a hollow tubular body, which is divided into an upper cavity and a lower cavity by a partition plate. The sidewall of the upper cavity is provided with an inner vent connected to the inner balloon, and the sidewall of the lower cavity is provided with an outer vent connected to the outer balloon. A rotary cavity switching mechanism is provided at the end of the partition plate away from the balloon for switching between the upper and lower cavities. The inner balloon comprises a balloon body, and an elastic binding membrane layer is provided in the middle of the balloon body. The present invention is characterized by being able to effectively improve the therapeutic effect of patients with pain in the ramus III region.

The present invention provides a biomarker combination for diagnosing Hirschsprung's disease, which is any one of combination 1, combination 2, and combination 3; wherein, the combination 1 is a combination of SCGN, PGP9.5, and S100; the combination 2 is a combination of SCGN and PGP9.5; the combination 3 is a combination of SCGN and S100. The present invention also provides the application of the above biomarker combination in the preparation of a diagnostic reagent for Hirschsprung's disease. At the same time, an immunohistochemistry kit is provided. The present invention discovers that SCGN can effectively identify ganglion cells in rectal mucosal biopsy specimens / entire colon specimens of children with Hirschsprung's disease, and the diagnostic sensitivity and specificity are higher than the existing detection schemes after combining with PGP9.5 and / or S100; the present invention provides a new, accurate, and sensitive detection method for the diagnosis of Hirschsprung's disease.

The application provides a toxicity-enhanced neurotoxin recombinant protein and application thereof, and belongs to the technical field of biological medicine. The recombinant protein comprises a botulinum toxin type A receptor binding domain and at least one GM1 binding peptide inserted into the botulinum toxin type A receptor binding domain, and the recombinin protein can recognize and bind to ganglioside GM1. The short peptide sequence capable of binding to ganglioside GM1 is introduced into the botulinum toxin type A receptor binding domain to obtain the recombinant protein, the binding capacity of the recombinant protein to ganglioside GM1 is enhanced, the target recognition and binding capacity of the recombinant protein to the nerve cell membrane are improved, the overall affinity and endocytosis efficiency of the recombinant protein to the nerve cell are improved, and the neurotoxicity of the botulinum toxin is enhanced. The application not only improves the binding efficiency of BoNT / A in the in-vitro nerve cell model, but also shows a higher toxicity level in the functional verification, and shows a good clinical conversion prospect.

The invention discloses lower limb dyskinesia adjusting equipment and a gait adjusting method, and the equipment comprises a wearing part which comprises a housing matched with a lower limb; the projection module comprises a projector arranged on the shell, and the projection angle of the projector is adjustable; the control unit comprises a control mainboard arranged in the shell and an acquisition module communicating with the control mainboard, and the acquisition module is configured to acquire gait data of the wearing piece in real time; the projector communicates with the control mainboard, and the control mainboard is configured to control and adjust the projection angle of the projector based on the gait data acquired by the acquisition module. The lower limb dyskinesia adjusting device prompts gait disorders by using vision, and the mechanism is that the lower limb dyskinesia adjusting device can provide external sensory cues for the patient and stimulate the visual system of the patient, so that neural activity of the premotor area is activated. Visual information is used for guiding gaits, and the deficiency of internal movement rhythm caused by basal ganglion dysfunction is made up.

The present disclosure pertains to the field of animal disease models, specifically to a method for constructing an animal model of open-angle glaucoma. In this model, the pathogenesis of open-angle glaucoma is mimicked by inducing necroptosis in trabecular meshwork cells through the injection of IFN-γ into the anterior chamber. This process leads to the inhibition of trabecular meshwork activity and functional impairment, resulting in elevated intraocular pressure and subsequent optic nerve changes indicative of glaucoma. The pathophysiological alterations observed in the animal model closely resemble those seen in human open-angle glaucoma, including chamber angle opening, trabecular meshwork dysfunction, increased intraocular pressure, and loss of RGCs.

The invention discloses Hangzhou white chrysanthemum-derived exosome-like nano-vesicles, a preparation method thereof and application of the nano-vesicles in treatment of optic nerve retinal degeneration diseases. In-vitro experiments show that the Hangzhou white chrysanthemum-derived exosome-like nano-vesicles provided by the invention can effectively inhibit glutamic acid-induced retinal cell oxidative stress and mitochondrial injury and improve the cell activity. In-vivo experiments show that the survival rate of ganglion cells in the retina of an NMDA injury model mouse can be remarkably improved by injecting the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle into a vitreous cavity, and the visual electrophysiological function of the NMDA injury model mouse can be improved. The invention provides a new thought and method for treatment of optic nerve retinal degeneration diseases, and has a wide application prospect. In addition, the preparation method of the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle provided by the invention is simple, and has the advantages of low cost, wide applicability, good safety, no animal-derived components and the like.

The application discloses application of a peripheral nervous system Mas-related G protein-coupled receptor D as a target point in preparation of a medicine for screening for relieving opioid tolerance. Jun The application further provides a medicine composition for regulating opioid tolerance, containing a Mas-related G protein-coupled receptor D siRNA sequence shown in SEQ ID NO. 1 or a siRNA sequence shown in SEQ ID NO. 2. The application further provides an in-situ hybridization kit for detecting expression of a Mas-related G protein-coupled receptor D gene in a dorsal root ganglion tissue of a peripheral nervous system. The application expands a new path for opioid companion diagnosis and intervention.

The invention provides sulfated monosialic acid ganglioside as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The structural formula of the ganglioside is 3GalNAc-4 (NeuAcS2 alpha2-3) Galbeta1-Cer, and the structural formula of the ganglioside is as shown in the specification. The sulfated monosialic acid ganglioside SJ-1 prepared by the invention has good activity, can be used for preparing medicines for promoting nerve regeneration or nourishing brain cells, and has a good application prospect.

The embodiment of the invention relates to the technical field of instrument data control, and discloses a non-invasive electrode closed-loop feedback stellate ganglion block electrical stimulation device. According to the device, a control module carries out closed-loop control processing on initial stimulation parameters and carries out adjustment processing on stimulation frequency and intensity to obtain an optimal control parameter combination; the acquisition module performs multi-dimensional acquisition processing on the physiological parameters to obtain a monitoring data set and performs threshold judgment processing to obtain a stimulation control instruction; the analysis module performs dynamic analysis processing on the monitoring data in the stimulation process to obtain a parameter adjustment strategy, and performs optimization processing on the stimulation parameters according to the parameter adjustment strategy to obtain steady-state control parameters; and the evaluation module carries out integration analysis processing on the control process data to obtain a working state evaluation index, and carries out classified statistical processing according to the evaluation index to obtain a parameter optimization suggestion. According to the invention, adaptive adjustment of the stimulation parameters and intelligent evaluation of the system operation state are realized.

The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and non-pungent derivatives of capsaicin, in their tautomeric forms and pharmaceutically acceptable salts, as the sole active ingredient, for use in the stimulation of the sphenopalatine ganglion and the enhancement of cerebral blood flow, to prevent or reduce brain injury resulting from decreased cerebral blood flow. The composition is administered via the oral transmucosal route, preferably in the form of a mucoadhesive tablet, and may be formulated for immediate or prolonged release, ensuring effective and tolerable absorption while avoiding the irritant effects associated with pungent capsaicin.

The invention discloses application of a peripheral nervous system Mas related G protein coupled receptor D as a target spot in preparing and screening a medicine for relieving opioid medicine tolerance. The invention also provides a pharmaceutical composition for regulating and controlling the tolerance of the opioid drugs. The pharmaceutical composition contains a Mas related G protein coupled receptor D siRNA sequence as shown in SEQ ID NO. 1 or a Jun siRNA sequence as shown in SEQ ID NO. 2. The invention also provides an in-situ hybridization kit for detecting the expression of the Mas related G protein coupled receptor D gene in the dorsal root ganglion tissue of the peripheral nervous system. According to the invention, a new path for accompanying diagnosis and intervention of opioid drugs is expanded.

A method is provided for stimulating a sphenopalatine ganglion (SPG) of a patient, the method including inserting a tube and an electrode mount into a nasal cavity of the patient and advancing the tube along a floor of the nasal cavity to near a posterior end of an inferior turbinate. One or more electrodes of the electrode mount are deployed superiorly away from the tube while the tube is disposed along the floor of the nasal cavity and the electrode mount is disposed within the nasal cavity, so as to bring at least one of the one or more electrodes into contact with a wall of the nasal cavity. A current configured to stimulate the SPG via the wall is applied to the one or more electrodes. Other embodiments are also described.